Featured Research

from universities, journals, and other organizations

Intense Chemotherapy Wards Off Recurrence In Half Of Mantle Cell Lymphoma Patients After Seven Years

Date:
December 15, 2008
Source:
University of Texas M. D. Anderson Cancer Center
Summary:
More than half of younger mantle cell lymphoma patients who received an intensive regimen of chemotherapy as front-line treatment remain in remission seven years later, researchers have reported.

More than half of younger mantle cell lymphoma patients who received an intensive regimen of chemotherapy as frontline treatment remain in remission seven years later, researchers at The University of Texas M. D. Anderson Cancer Center report December 9 at the 50th annual meeting of the American Society of Hematology.

Among patients 65 or younger, 52 percent survived without disease recurrence at a median of seven years of follow-up, said first author Jorge Romaguera, M.D., professor in M. D. Anderson's Department of Lymphoma and Myeloma. Overall survival for this subgroup was 68 percent.

"There is some disagreement about whether these younger patients should receive a bone marrow transplant as frontline therapy rather than chemotherapy," Romaguera said. "Our results with chemotherapy are as good as any transplant data. We don't believe a transplant is necessary as a first treatment in newly diagnosed mantle cell lymphoma."

Mantle cell lymphoma is one of the most lethal versions of non-Hodgkin lymphoma. Romaguera and colleagues have followed 97 patients for up to nine years who received rituximab plus a combination of chemotherapies known as hyperCVAD, alternated with rituximab plus high-dose methotrexate/cytarabine in 6-8 cycles.

Out of those patients, 87 percent achieved either a complete response or unconfirmed complete response after six cycles. Of 65 patients who were 65 or younger, 30 relapsed. Of 32 patients older than 65, a total of 23 relapsed.

Overall survival for the entire group, including all ages up to 80 years, was 60 percent; 43 percent were at failure-free survival, with no recurrence of the disease, at seven years of median follow-up.

Survival is about the same for patients who undergo stem cell transplantation, Romaguera said. No randomized studies between the chemotherapy regimen, stem cell transplants or the chemotherapy plus stem cell transplant have been done.

About 3,500 new cases of mantle cell lymphoma are diagnosed in the United States annually. The average age of diagnosis is the mid-sixties and median survival is about four years.

The ongoing research is funded by the Getz Family Fund for Mantle Cell Lymphoma Research, the Rich Family Fund for Lymphoma Research and the Lowell and Rebecca Whitlock Fund for Mantle Cell Lymphoma Research.

Co-authors with Romaguera are Luis Fayad, M.D., Alma Rodriguez, M.D., Fredrick Hagemeister, M.D., Barbara Pro, M.D., Peter McLaughlin, M.D., Anas Younes, M.D., Felipe Samaniego, M.D., Jatin Shah, M.D., Kim Hartig, Fernando Cabanillas, M.D., Larry Kwak, M.D., Ph.D. and Michael Wang, M.D., all of M. D. Anderson's Department of Lymphoma and Myeloma; and Hagop Kantarjian, M.D., of the Department of Leukemia.


Story Source:

The above story is based on materials provided by University of Texas M. D. Anderson Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

University of Texas M. D. Anderson Cancer Center. "Intense Chemotherapy Wards Off Recurrence In Half Of Mantle Cell Lymphoma Patients After Seven Years." ScienceDaily. ScienceDaily, 15 December 2008. <www.sciencedaily.com/releases/2008/12/081209125832.htm>.
University of Texas M. D. Anderson Cancer Center. (2008, December 15). Intense Chemotherapy Wards Off Recurrence In Half Of Mantle Cell Lymphoma Patients After Seven Years. ScienceDaily. Retrieved April 20, 2014 from www.sciencedaily.com/releases/2008/12/081209125832.htm
University of Texas M. D. Anderson Cancer Center. "Intense Chemotherapy Wards Off Recurrence In Half Of Mantle Cell Lymphoma Patients After Seven Years." ScienceDaily. www.sciencedaily.com/releases/2008/12/081209125832.htm (accessed April 20, 2014).

Share This



More Health & Medicine News

Sunday, April 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Nine-Month-Old Baby Can't Open His Mouth

Nine-Month-Old Baby Can't Open His Mouth

Newsy (Apr. 19, 2014) Nine-month-old Wyatt Scott was born with a rare disorder called congenital trismus, which prevents him from opening his mouth. Video provided by Newsy
Powered by NewsLook.com
'Holy Grail' Of Weight Loss? New Find Could Be It

'Holy Grail' Of Weight Loss? New Find Could Be It

Newsy (Apr. 18, 2014) In a potential breakthrough for future obesity treatments, scientists have used MRI scans to pinpoint brown fat in a living adult for the first time. Video provided by Newsy
Powered by NewsLook.com
Little Progress Made In Fighting Food Poisoning, CDC Says

Little Progress Made In Fighting Food Poisoning, CDC Says

Newsy (Apr. 18, 2014) A new report shows rates of two foodborne infections increased in the U.S. in recent years, while salmonella actually dropped 9 percent. Video provided by Newsy
Powered by NewsLook.com
Scientists Create Stem Cells From Adult Skin Cells

Scientists Create Stem Cells From Adult Skin Cells

Newsy (Apr. 17, 2014) The breakthrough could mean a cure for some serious diseases and even the possibility of human cloning, but it's all still a way off. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins